LabGenomics USA Acquires Integrated Molecular Diagnostics (IMD) CLIA Labs
October 25, 2024
LabGenomics USA acquired Integrated Molecular Diagnostics (IMD) CLIA labs, expanding its U.S. footprint to four CLIA-certified laboratories and strengthening its molecular and oncology diagnostic capabilities. The deal broadens LabGenomics' geographic reach across the U.S. coasts and positions the company to launch new laboratory-developed tests (LDTs) and expand reimbursable services.
- Buyers
- LabGenomics USA
- Targets
- Integrated Molecular Diagnostics (IMD) CLIA labs
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
LabGenomics USA LLC Acquires QDx Pathology
September 5, 2023
Healthcare Services
LabGenomics USA LLC, a subsidiary of South Korea–based LabGenomics Co., Ltd., has acquired QDx Pathology, a U.S. clinical and molecular pathology laboratory. The deal, signed in August 2023, is intended to accelerate LabGenomics' entry and expansion into the North American diagnostics market by combining QDx's lab services with LabGenomics' NGS-based molecular diagnostics capabilities.
-
Labcorp Acquires Personal Genome Diagnostics (PGDx)
February 21, 2022
Healthcare Services
Labcorp has completed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a cancer genomics company focused on liquid biopsy and tissue-based genomic products and services. The deal builds on and expands Labcorp’s oncology and next-generation sequencing (NGS) capabilities and liquid biopsy offerings.
-
MLM Medical Labs Acquires MD Biosciences, Inc.
October 27, 2020
Healthcare Services
MLM Medical Labs, a Great Point Partners portfolio company, has acquired MD Biosciences, Inc., an Oakdale, Minnesota-based provider of preclinical, translational and clinical-phase contract research services. The deal expands MLM's U.S. footprint and adds immunohistochemistry, preclinical research and histopathology capabilities to its global laboratory platform as part of an integration with recent U.S. additions such as CirQuest Labs.
-
Canopy Biosciences Acquires Core Diagnostics
December 4, 2019
Biotechnology
Canopy Biosciences, a St. Louis-based multi-omic services company backed by Ampersand Capital Partners, has acquired Core Diagnostics, a California CLIA-certified biomarker analysis laboratory. The acquisition gives Canopy CLIA-certified laboratory capabilities to offer its multi-omic immune profiling services to clinical as well as preclinical and translational customers.
-
LabCorp Acquires MNG Laboratories from HealthEdge
March 4, 2019
Healthcare Services
LabCorp has acquired MNG Laboratories, an Atlanta-based clinical diagnostic provider specializing in neurogenetics and next-generation sequencing, from HealthEdge Investment Partners' Fund II. The acquisition expands LabCorp’s neurology and neurogenetics testing capabilities and makes MNG’s testing services available through LabCorp’s Covance drug development business.
-
ICON plc Acquires MolecularMD Corporation
February 21, 2019
Healthcare Services
ICON plc acquired MolecularMD Corporation, a molecular diagnostic specialty laboratory, to expand ICON's molecular diagnostic testing capabilities—including next-generation sequencing and immunohistochemistry—and strengthen support for oncology drug–diagnostic co-development. The acquisition integrates MolecularMD's central laboratory services and client base into ICON's global laboratory network to support precision medicine programs across clinical development phases.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.